aTyr Pharma releases results of early-onset FSHD trial

SAN DIEGO, April 24, 2017 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced promising clinical results from its Phase 1b/2 003 trial assessing the safety and potential activity of Resolaris™ in patients with early onset facioscapulohumeral muscular dystrophy (FSHD).

Read the full press release here.


2 responses to “aTyr Pharma releases results of early-onset FSHD trial”

  1. I was recently diagnosed with FSH muscular dystrophy. My shoulders are deteriorating very fast. I feel my bones in my shoulders just sitting her typing this. If there is a treatment of any kind that may slow this down or get rid of it without terrible side effects I am interested, Thank You.

    • It will take some years to develop treatments to slow or stop the degeneration of muscle, but in the meantime, exercise can make a significant difference. Download our physical therapy brochure to help you and your physical therapist develop exercises customized to your needs. Winging shoulder blades can be corrected through surgery, but this option is not for everyone.

Leave a Reply

Your email address will not be published. Required fields are marked *